A transmembrane-modified version of tumor-targeting peptide A7R self-assembles into nanoparticles that simultaneously target tumor blood vessels and deliver anti-cancer cargo, reducing tumor growth in mice.
Dual-function peptideTM-A7R simultaneously targets tumor vasculature via VEGFR2/NRP-1 and delivers therapeutic payloads as self-assembled nanoparticles
What the researchers found
Transmembrane-modified A7R peptide self-assembled into nanoparticles that targeted VEGFR2/NRP-1 on tumor vessels, inhibited angiogenesis, and served as a molecular carrier for therapeutic delivery.
Why it matters
Creating a single molecule that both targets tumor vessels and carries drug payloads simplifies cancer drug design and could improve treatment by combining targeting and therapy in one step.
The numbers in context
A7R (ATWLPPR) was modified with arginine and glutamic acid substitutions, cyclized, and linked to a membrane-permeation sequence.
How the study worked
Peptide modification and nanoparticle self-assembly characterization. Tested anti-angiogenic and tumor-targeting properties in cell culture and mouse tumor models.
Who was studied
In vitro characterization of modified A7R peptide for tumor targeting and drug delivery
What this study cannot tell us
Preclinical study. Self-assembly behavior may differ in human blood. Specific therapeutic payload and dosing not fully optimized. Animal model results may not translate directly.
How to read the evidence
Preliminary evidence: proof-of-concept preclinical study demonstrating novel peptide modification approach for tumor targeting and drug delivery.
When this study was published
Published in 2024. Novel approach to dual-function peptide nanoparticle design.
The bigger picture
Most cancer drug delivery systems require separate targeting and payload components. This dual-function peptide approach could simplify nanomedicine design while improving tumor-specific delivery.
Questions still open
- Can TM-A7R nanoparticles deliver a range of cancer drugs beyond the ones tested?
- How does TM-A7R stability compare to other tumor-targeting peptide systems in vivo?
- Would this approach work in human tumors with varying VEGFR2/NRP-1 expression?
Common questions
What is A7R peptide?
How does this differ from other cancer drug delivery systems?
Read the original research
Transmembrane modification of tumor vascular targeting peptide A7R as molecular cargo delivery tool.
Bioorganic chemistry, 145, 107240
Citation
Zhang, Qingqing; Yang, Zeyu; Zhang, Jie; Li, Yanchen; Dang, Xintao; Qu, Jingkun; Pan, Xiaoyan; Zhang, Jie. (2024). Transmembrane modification of tumor vascular targeting peptide A7R as molecular cargo delivery tool.. Bioorganic chemistry, 145, 107240. https://doi.org/10.1016/j.bioorg.2024.107240